Dragon Pharmaceutical is looking to build a pharmaceutical empire in the PRC. Headquartered in Canada, the company has production facilities within mainland China that manufacture active pharmaceutical ingredients (APIs), intermediates, and finished formulations. It sells its bulk APIs and intermediates, which are used in antibiotic formulations, both in China and internationally (mainly in India). Its finished products (sold only in China) are primarily injectable cephalosporin antibiotics. In 2007 Dragon Pharmaceutical divested its biotech division in order to focus on its core antibiotic operations. CEO Yanlin Han holds nearly half of the company's stock and is seeking to buy the balance.

DARA BioSciences, Inc. (DARA), formerly Point therapeutics, Inc. is a development stage pharmaceutical company that acquires therapeutic molecules and medical technologies from third parties, and advances their clinical development for later sale to pharmaceutical and biotechnology companies. DARA focuses on two drug development programs: KRN5500 for neuropathic pain in cancer patients and DB959 for type 2 diabetes. On February 12, 2008, Point and DARA BioSciences, Inc. completed their merger transaction, in which DP Acquisition Corp. (a wholly owned subsidiary of Point) merged with and into DARA BioSciences, Inc.

Anadys Pharmaceuticals was founded in 1992 and is headquartered in San Diego, California. Anadys Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing medicines in the areas of hepatitis C and oncology. It develops ANA598, a small-molecule non-nucleoside inhibitor of the NS5B polymerase for the treatment of hepatitis C; and ANA773, an oral toll-like receptor 7 agonist prodrug for the treatment of hepatitis C and cancer. The company was formerly known as Scriptgen Pharmaceuticals, Inc. and changed its name to Anadys Pharmaceuticals, Inc. in May 2000.

Ferndale Laboratories makes prescription and over the counter medications, with a primary focus on skin care maladies, including acne, dry skin, eczema, psoriasis, and inflammation. The company also makes topical pain relief creams, surgical adhesives and adhesive removers, and decongestants. Ferndale Laboratories markets its products to physicians and consumers. Ferndale company originally began selling vitamins, tonics, elixirs, and surgical instruments. It was founded in Detroit in 1897 as J. F. Hartz Company, the name it operated under until the mid-1950s when it changed its name to Ferndale Laboratories.

OrthoLogic Corp., doing business as Capstone Therapeutics, focuses on the development and commercialization of therapeutic peptides and other molecules for patients with under-served conditions. The company's product includes Chrysalin, or TP508, a 23-amino acid synthetic peptide, which is under pre-clinical testing for vascular applications, such as acute myocardial infarction and chronic myocardial ischemia. It also offers AZX100, a synthetic 24-amino acid peptide to relax smooth muscle, which modulates blood pressure and the function of blood vessels, airways, sphincters, the gastrointestinal tract, and the genitourinary tract. AZX100 is also evaluated for medical and commercial applications, such as treatment of pulmonary disease, prevention of hypertrophic and keloid scarring, and intimal hyperplasia. The company was formerly known as IatroMed, Inc. and changed its name to OrthoLogic Corp. in July 1991. OrthoLogic Corp. was founded in 1987 and is based in Tempe, Arizona.

Callisto Pharmaceuticals, Inc. was founded in 1996 and is headquartered in New York, New York. Callisto Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses primarily on the development of drugs to treat gastrointestinal disorders and diseases, rheumatoid arthritis, neuroendocrine cancer, and acute leukemia. The company has three drugs in development, which include SP-304, a guanylyl cyclase C receptor agonist for the treatment of chronic constipation and constipation-predominant irritable bowel syndrome, which has completed Phase I clinical trial; Atiprimod, an orally administered drug with antiproliferative, anti-inflammatory and antiangiogenic activities, which is in Phase II development for advanced carcinoid cancer; and L-Annamycin, a novel compound from the anthracycline family of proven anti-cancer drugs for the treatment of leukemia. It also focuses on the development of Atiprimod for the treatment of rheumatoid arthritis. The company has license agreements with AnorMED Inc. to research, develop, sell, and commercialize the Atiprimod patent rights; and the University of Texas M.D. Anderson Cancer Center to develop and commercialize the L-Annamycin patent rights.

Founded in 1929, the not-for-profit organization is a leading researcher of human diseases, their causes, and their potential cures. Much of its research into mammalian genetics is focused on mice, which share a similar genetic makeup to humans. In addition to its own research in areas such as cancer, immunology, and metabolic disease, the organization maintains colonies of mice and supplies them under the brand name JAX to other laboratories around the globe. Additionally, The Jackson Laboratory offers educational programs -- including internships, workshops, and predoctoral programs -- for both current and future scientists.

STADA Arzneimittel AG (STADA) is a Germany-based company active in the pharmaceutical sector, concentrating on the development and marketing of products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are: Generics, comprised of low-priced and active-ingredient products, and Branded Products, focusing on multisource products that are accessible without active ingredient research. STADA’s generic drugs are marketed by the Group subsidiary, STADApharm GmbH, through a sales network including Austria, Belgium, Bosnia, Portugal and the United Kingdom. Its branded products are distributed internationally as well, in such countries as Bulgaria, the Czech Republic, Denmark, Russia, Thailand and Vietnam. The Company operates through subsidiaries located in Germany, Switzerland, Russia, Macedonia, Serbia, Montenegro, Bulgaria, Romania and Poland, as well as in the United States.

Abbott GmbH wants to cure what ails you. A subsidiary of Abbott Labs, the company has production facilities in four German cities. The Wiesbaden facility produces biopharmaceuticals used to treat rheumatoid arthritis and HIV/AIDS, as well as hospital and nutritional products. It also houses the company's diagnostics sales department. The Ludwigshafen complex (one of Abbott's largest pharmaceutical production sites outside the US) is home to Abbott Labs' European clinical trials, high-tech drug production, and R&D operations. Wetzlar houses Abbott Vascular Management while Rangendingen houses a vascular instrument manufacturing plant where balloon catheters, stents, and stent delivery systems are made.

Metabolex, Inc. was founded in 1991 and is based in Hayward, California. Metabolex, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of type II diabetes and related metabolic disorders. The company’s products include MBX-102/JNJ 39659100, an oral small-molecule insulin sensitizer; MBX-8025, which is intended for the treatment of dyslipidemia; MBX-2982, which is an agonist of GPR119, a G-protein coupled receptor that is expressed in pancreatic islets and the gastrointestinal tract; and MBX-2044, a second generation insulin sensitizer.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.